{"analyses":[{"ciLowerLimit":"0.28","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.63","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"One-sided","paramType":"Hazard Ratio (HR)","paramValue":"0.42","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to low number of PFS events","groupId":"OG000","lowerLimit":"28.1","upperLimit":"NA","value":"33.7"},{"comment":"Not estimable due to low number of PFS events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"241"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first, as assessed by the ICR per 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines with modifications for treatment-related lymphocytosis in participants with CLL and the Revised Criteria for Response for Malignant Lymphoma in participants with small lymphocytic lymphoma (SLL).","dispersionType":"95% Confidence Interval","groups":[{"description":"Bendamustine + Rituximab in participants with CLL without del(17p); bendamustine 90 milligrams (mg)/m\\^2/day administered intravenously (IV) on the first 2 days of each cycle for 6 cycles; rituximab 375 mg/m\\^2 for Cycle 1 and 500 mg/m\\^2 for Cycles 2 to 6 (each cycle is 28 days)","id":"OG000","title":"Cohort 1: Bendamustine + Rituximab Without Del(17p)"},{"description":"Zanubrutinib in participants with CLL without del(17p); 160 mg administered twice a day until unacceptable toxicity or disease progression","id":"OG001","title":"Cohort 1: Zanubrutinib Without Del(17p)"}],"paramType":"MEDIAN","populationDescription":"ITT analysis set included all enrolled participants who were assigned to a treatment group","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years and 7 months (as of cut-off date of 07MAY2021)","title":"Cohort 1: Progression-free Survival (PFS) as Determined by Independent Central Review (ICR)","type":"PRIMARY","unitOfMeasure":"Months"}